CoChat

Disparities in Diabetes Technology Uptake in Youth and Young Adults With Type 1 Diabetes: A Global Perspective

Conway, Rebecca Baqiyyah, Snell-Bergeon, Janet, Honda-Kohmo, Kyoko, Peddi, Anil Kumar, Isa, Salbiah Binti, Sulong, Shakira, Sibomana, Laurien, Gerard Gonzalez, Andrea, Song, Jooyoun, Lomax, Kate Elizabeth, Lo, Ching-Nien, Kim, Wondong, Haynes, Aveni, de Bock, Martin, Burckhardt, Marie-Anne, Schwab, Savannah, Hong, Kwanho · 2024 · Journal of the Endocrine Society
Cited by 31

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries. This review focuses on disparities in diabetes technology use among adolescents and young adults with T1D, barriers to access and use, and summarizes common themes emerging across countries and regions. We conducted a survey among medical technology manufacturers and physicians in various countries across diverse geographical regions and performed extensive literature searches. Across all countries and regions, economic barriers stand out as the largest and most common barriers, either preventing market penetrance of technology into a country or limiting its access to the individual with diabetes due to high out of pocket costs. Other common barriers include structural or accessibility barriers, such as stringent eligibility requirements by insurance providers, regardless of whether the insurance was private or government-based, and provider/individual level barriers. Based on the evidence presented, we suggest the need for a joint effort involving governments, private health insurers, technology manufacturers, and healthcare providers to address the global disparities of diabetic technology utilization and ensure equitable access for all individuals living with T1D worldwide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jendso/bvae210

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 57

  1. Shah, 2021, A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec, Diabetes Obes Metab, 23, 1936, 10.1111/dom.14423 · DOI
  2. Dubé, 2013, Glucose or intermittent high-intensity exercise in glargine/glulisine users with T1DM, Med Sci Sports Exerc, 45, 3, 10.1249/MSS.0b013e31826c6ad3 · DOI
  3. Maahs, 2014, The effects of lowering nighttime and breakfast glucose levels with sensor-augmented pump therapy on hemoglobin A1c levels in type 1 diabetes, Diabetes Technol Ther, 16, 284, 10.1089/dia.2013.0227 · DOI
  4. Yardley, 2013, Insulin pump therapy is associated with less post-exercise hyperglycemia than multiple daily injections: an observational study of physically active type 1 diabetes patients, Diabetes Technol Ther, 15, 84, 10.1089/dia.2012.0168 · DOI · Paper page
  5. Berget, 2021, Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: identifying a clinical target for hybrid closed-loop use, Diabetes Obes Metab, 23, 2048, 10.1111/dom.14441 · DOI · Paper page
  6. Akturk, 2020, Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes, Diabetes Obes Metab, 22, 583, 10.1111/dom.13933 · DOI · Paper page
  7. Nakhla, 2019, Identifying pediatric diabetes cases from health administrative data: a population-based validation study in Quebec, Canada, Clin Epidemiol, 11, 833, 10.2147/CLEP.S217969 · DOI
  8. Simba, 2023, Socioeconomic disparities in glycemic management in children and youth with type 1 diabetes: a retrospective cohort study, Can J Diabetes, 47, 658, 10.1016/j.jcjd.2023.07.005 · DOI
  9. Faradji-Hazán, 2021, Type 1 diabetes care in Mexico: an analysis of the RENACED-DT1 national registry, Rev Invest Clin, 73, 222
  10. Kim, 2020, Current status of continuous glucose monitoring among Korean children and adolescents with type 1 diabetes mellitus, Ann Pediatr Endocrinol Metab, 25, 145, 10.6065/apem.2040038.019 · DOI
  11. Choe, 2022, Temporal trends for diabetes management and glycemic control between 2010 and 2019 in Korean children and adolescents with type 1 diabetes, Diabetes Technol Ther, 24, 201, 10.1089/dia.2021.0274 · DOI
  12. Mohd Nor, 2024, Self-care management among children and adolescents with diabetes mellitus in Malaysia, J Child Health Care, 28, 804, 10.1177/13674935231168911 · DOI
  13. Sifunda, 2023, Prevalence and psychosocial correlates of diabetes mellitus in South Africa: results from the South African national health and nutrition examination survey (SANHANES-1), Int J Environ Res Public Health, 20, 5798, 10.3390/ijerph20105798 · DOI
  14. Lomax, 2023, Socioeconomic status and diabetes technology use in youth with type 1 diabetes: a comparison of two funding models, Front Endocrinol (Lausanne), 14, 1178958, 10.3389/fendo.2023.1178958 · DOI
  15. Lorenzen, 2024, Associations between use of diabetes technology and diabetes distress: a Danish cross-sectional survey of adults with type 1 diabetes, BMJ Open, 14, e080053, 10.1136/bmjopen-2023-080053 · DOI
  16. Bratke, 2022, Relation of health-related quality of life with glycemic control and use of diabetes technology in children and adolescents with type 1 diabetes: results from a national population based study, J Diabetes Res, 2022, 8401328, 10.1155/2022/8401328 · DOI
  17. Svensson, 10.18158/ryNUNVPiu · doi:10.18158/rynunvpiu
  18. Lee, 2022, Overcoming barriers to diabetes technology in youth with type 1 diabetes and public insurance: cases and call to action, Case Rep Endocrinol, 2022, 9911736
  19. Yamamoto, 2019, Status and trends in the use of insulin analogs, insulin delivery systems and their association with glycemic control: comparison of the two consecutive recent cohorts of Japanese children and adolescents with type 1 diabetes mellitus, J Pediatr Endocrinol Metab, 32, 1, 10.1515/jpem-2018-0329 · DOI
  20. Shimmura, 2018, Problems with real-time CGM and CSII (in Japanese), Curr Treat Diabetes, 9, 188
  21. Ong, 2014, Barriers and facilitators to self-monitoring of blood glucose in people with type 2 diabetes using insulin: a qualitative study, Patient Prefer Adherence, 8, 237
  22. Burnside, 2023, Inequity in access to continuous glucose monitoring and health outcomes in paediatric diabetes, a case for national continuous glucose monitoring funding: a cross-sectional population study of children with type 1 diabetes in New Zealand, Lancet Reg Health West Pac, 31, 100644
  23. Rotondi, 2022, Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently scanned continuous glucose monitoring technologies for adults with type 1 diabetes in Canada: a modeling study, Diabetes Care, 45, 2012, 10.2337/dc21-2341 · DOI
  24. Diabetes Canada Clinical Practice Guidelines Expert Working Group, 2021, Blood glucose monitoring in adults and children with diabetes: update 2021, Can J Diabetes, 45, 580, 10.1016/j.jcjd.2021.07.003 · DOI
  25. Conway, 2023, Racial disparities in diabetes technology adoption and their association with HbA1c and diabetic ketoacidosis, Diabetes Metab Syndr Obes, 16, 2295, 10.2147/DMSO.S416192 · DOI
  26. Paris, 2009, Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for diabetes in youth study, J Pediatr, 155, 183, 10.1016/j.jpeds.2009.01.063 · DOI
  27. Snyder, 2019, Socio-economic, demographic, and clinical correlates of poor glycaemic control within insulin regimens among children with type 1 diabetes: the SEARCH for diabetes in youth study, Diabet Med, 36, 1028, 10.1111/dme.13983 · DOI
  28. Grassi, 2023, Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system, Diabetes Obes Metab, 25, 1688, 10.1111/dom.15023 · DOI · Paper page
  29. Antonio-Villa, 2021, Glycemic control, treatment and complications in patients with type 1 diabetes amongst healthcare settings in Mexico, Diabetes Res Clin Pract, 180, 109038, 10.1016/j.diabres.2021.109038 · DOI
  30. Patel, 2013, Diabetes mellitus: the Latin American paradox, Int J Clin Pract, 67, 1217, 10.1111/ijcp.12257 · DOI
  31. Borges, 2024, The impact of diabetes education on continuous glucose monitoring in SUS-dependent patients in a northeastern Brazilian city, Life (Basel), 14, 10.3390/life14030320 · DOI
  32. Bahia, 2023, Cost-effectiveness of continuous glucose monitoring with FreeStyle Libre® in Brazilian insulin-treated patients with types 1 and 2 diabetes mellitus, Diabetol Metab Syndr, 15, 242, 10.1186/s13098-023-01208-5 · DOI
  33. Green, 2021, Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults, Diabetologia, 64, 2741, 10.1007/s00125-021-05571-8 · DOI · Paper page
  34. Kawasaki, 2006, Type 1 diabetes in Japan, Diabetologia, 49, 828, 10.1007/s00125-006-0213-8 · DOI
  35. Onda, 2017, Incidence and prevalence of childhood-onset type 1 diabetes in Japan: the T1D study, Diabet Med, 34, 909, 10.1111/dme.13295 · DOI · Paper page
  36. Matsuda, 2023, Long-term trends of pediatric type 1 diabetes incidence in Japan before and after the COVID-19 pandemic, Sci Rep, 13, 5803, 10.1038/s41598-023-33037-x · DOI
  37. Lee, 2023, Glycemia according to the use of continuous glucose monitoring among adults with type 1 diabetes mellitus in Korea: a real-world study, Diabetes Metab J, 47, 405, 10.4093/dmj.2022.0032 · DOI
  38. Lu, 2021, Overall and cause-specific mortality in patients with type 1 diabetes mellitus: a population-based cohort study in Taiwan from 1998 through 2014, J Epidemiol, 31, 503, 10.2188/jea.JE20200026 · DOI
  39. Hussein, 2018, Diabetes care in Malaysia: problems, new models, and solutions, Ann Glob Health, 81, 851, 10.1016/j.aogh.2015.12.016 · DOI
  40. 2015, Management of Type 1 Diabetes Mellitus in Children & Adolescents
  41. Fralick, 2022, Global accessibility of therapeutics for diabetes mellitus, Nat Rev Endocrinol, 18, 199, 10.1038/s41574-021-00621-y · DOI
  42. Kiran, 2023, Use of continuous glucose monitoring system in children with type 1 diabetes mellitus in a resource limited setting, Indian J Endocrinol Metab, 27, 208, 10.4103/ijem.ijem_376_22 · DOI
  43. Swaminathan, 2023, One-year follow-up of 50 rural underprivileged type 1 diabetes children on insulin pump therapy: breaking socio-economic barriers in diabetes technologies, Indian J Endocrinol Metab, 27, 213, 10.4103/ijem.ijem_324_22 · DOI
  44. Mandaviya, 2022, Guidelines for Management of Type 1 Diabetes
  45. Atun, 2017, Diabetes in sub-Saharan Africa: from clinical care to health policy, Lancet Diabetes Endocrinol, 5, 622, 10.1016/S2213-8587(17)30181-X · DOI · Paper page
  46. Beran, 2019, A perspective on global access to insulin: a descriptive study of the market, trade flows and prices, Diabet Med, 36, 726, 10.1111/dme.13947 · DOI
  47. Virmani, 2022, ISPAD clinical practice consensus guidelines 2022: management of the child, adolescent, and young adult with diabetes in limited resource settings, Pediatr Diabetes, 23, 1529, 10.1111/pedi.13456 · DOI
  48. Karges, 2017, Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes, JAMA, 318, 1358, 10.1001/jama.2017.13994 · DOI · Paper page
  49. Kordonouri, 2020, Determinants of glycaemic outcome in the current practice of care for young people up to 21 years old with type 1 diabetes under real-life conditions, Diabet Med, 37, 797, 10.1111/dme.14130 · DOI
  50. DeSalvo, 2022, Transatlantic comparison of pediatric continuous glucose monitoring use in the diabetes-patienten-verlaufsdokumentation initiative and type 1 diabetes exchange quality improvement collaborative, Diabetes Technol Ther, 24, 920, 10.1089/dia.2022.0248 · DOI
  51. Auzanneau, 2023, Area deprivation and demographic factors associated with diabetes technology use in adults with type 1 diabetes in Germany, Front Endocrinol (Lausanne), 14, 1191138, 10.3389/fendo.2023.1191138 · DOI
  52. Dennig, 2022, Stable metabolic control but increased demand for professional support in children with type 1 diabetes in the past ten years in Bern/Switzerland: a quality control study, J Diabetes Res, 2022, 3170558, 10.1155/2022/3170558 · DOI
  53. Kubiak, 2020, Psychosocial aspects of diabetes technology, Diabet Med, 37, 448, 10.1111/dme.14234 · DOI
  54. Kubiak, 2016, Psychosocial aspects of continuous glucose monitoring: connecting to the patients’ experience, J Diabetes Sci Technol, 10, 859, 10.1177/1932296816651450 · DOI · Paper page
  55. Borges, 2016, Continuous glucose monitoring in type 1 diabetes, J Diabetes Sci Technol, 10, 633, 10.1177/1932296816634736 · DOI
  56. Vloemans, 2017, Keeping safe. Continuous glucose monitoring (CGM) in persons with type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study, Diabet Med, 34, 1470, 10.1111/dme.13429 · DOI
  57. Ogle, 2019, Levels of type 1 diabetes care in children and adolescents for countries at varying resource levels, Pediatr Diabetes, 20, 93

Cited by

Metadata

Authors
Conway, R. B., Snell-Bergeon, J., Honda-Kohmo, K., Peddi, A. K., Isa, S. B., Sulong, S., Sibomana, L., Gerard Gonzalez, A., Song, J., Lomax, K. E., Lo, C.-N., Kim, W., Haynes, A., de Bock, M., Burckhardt, M.-A., Schwab, S., & Hong, K.
Affiliations
  • Department of Epidemiology, University of Colorado , Aurora, CO 80045 ,
  • Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado , Aurora, CO 80045 ,
  • Division of Preventative Healthcare, National Cerebral and Cardiovascular Center , Suita, Osaka 564-8565 ,
  • Technical Head, Cgenic Meditech Pvt Ltd , Gujarat 390020 ,
  • Universiti Sains Malaysia, Advanced Medical and Dental Institute , 130200 Pulau, Pinang ,
  • Division of Medical Operations, Metro Sihat Sdn Bhd , 60000 Kuala Lumpur ,
  • Department of the Director, Pillar of Health , Pittsburgh, PA 15237 ,
  • Department of Psychiatry, Jooyoun's Psychiatry , 07938 Seoul ,
  • Department of Endocrinology and Diabetes, Perth Children's Hospital , Nedlands, WA 6909 ,
  • GM Office, EPS BIO Technology Corp. , Hsinchu 30076 ,
  • Management (Including R&D Director), CareforU Co., Ltd. , 14042 Anyang ,
  • Children's Diabetes Centre, Telethon Kids Institute, The University of Western Australia , Nedlands, WA 6909 ,
  • Department of Pediatrics, University of Otago , Christchurch 8140 ,
  • University Children's Hospital Basel UKBB, Pediatric Endocrinology and Diabetology , 4056 Basel ,
  • Management (Marketing & Development), CareforU Co., Ltd. , 14042 Anyang ,
Venue
Journal of the Endocrine Society
Published
2024-11-26
Volume
9
Issue
1
ISSN
2472-1972
Cited by
31
References
12
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.